12:00 AM
Sep 05, 2016
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afluria Quadrivalent regulatory update

FDA approved an sBLA from CSL’s Seqirus unit for Afluria Quadrivalent to prevent infection from 2 influenza subtypes A and 2 influenza type B viruses contained in the...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >